Background: Cocoa flavanols may improve cardiometabolic health. Evidence from small short-term randomized clinical
Introduction
Cardiometabolic diseases are among the leading causes of morbidity and mortality worldwide (1, 2) . In observational studies, dietary intake of flavanol-rich cocoa products, such as dark chocolate, has been associated with a reduced risk of cardiometabolic diseases, including cardiovascular disease (3), hypertension (4), metabolic syndrome (5) , and diabetes (6) . Given these possible protective effects on cardiometabolic health, cocoa products may add to the armamentarium of bioactives.
Cocoa products are generally considered a source of dietary flavanols that may underlie their purported health benefits (5) (6) (7) (8) , although their flavanol profile and content vary by cultivars and fermentation procedures. Evidence from previous meta-analyses of randomized clinical trials (RCTs) 10 suggest that chocolate, Synthesized evidence from observational studies has also shown that chocolate consumption may reduce the risk of ischemic heart disease (12) and stroke (13) . Hypothesized mechanisms that underlie potential associations between cocoa flavanols and a reduced risk of chronic diseases include improvements in the lipid profile (14) , insulin sensitivity (15, 16) , and endothelial function (17) and the alleviation of systemic inflammation (18) , thrombosis (19, 20) , and oxidation (14, 21) . We therefore conducted a meta-analysis of RCTs to assess the effects of cocoa flavanol intake on a variety of circulating cardiometabolic biomarkers. We also examined whether the effects of cocoa flavanols differ by study design, participant age, sex, intervention duration, existing comorbidities, and the form and amount of cocoa flavanol intake.
Methods
Data sources and searches. We followed a standardized protocol in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to conduct this meta-analysis (22) . Two investigators independently conducted literature searches of PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials published from January 1965 (index date) to December 2015 with the use of terms from Medical Subject Headings, including cacao, cocoa, chocolate, clinical trial, controlled clinical trial, and RCT. The search was limited to trials on human participants and articles in English. All relevant studies and review articles (including meta-analysis) and the reference lists of the identified articles were checked manually. Any disagreement between the 2 investigators was resolved by consensus. An institutional review board review was not applicable because we conducted a systematic review and meta-analysis, which do not directly involve human subjects.
Study selection. Articles were included if the study was 1) an RCT that assigned $1 group of participants to cocoa products, chocolate, or cocoa flavanol supplements and 1 group to placebo and 2) circulating cardiometabolic biomarkers in blood samples, including plasma, serum, and whole blood, were measured at baseline and at the end of each intervention. All abstracts that reported the effects of cocoa flavanols on cardiometabolic biomarkers were included for screening. Studies were excluded if 1) the study design was not an RCT or there was no placebo group; 2) the intervention was not cocoa products, chocolate, or cocoa flavanol supplements; 3) the biomarker concentrations were monitored #1 wk after the acute intervention; 4) the amount of cocoa flavanols in the active intervention was <100 mg/d; 5) the participants were pregnant women, children, or adolescents; or 6) values of outcome measures at the end of the trial or changes from baseline were not reported.
In total, 320 articles were retrieved from the literature search, and 6 additional articles were retrieved from cross-reference and expert sources ( Figure 1) . We excluded 239 articles after reviewing the titles and abstracts and 68 more after examining the full text. The final set of articles for our systematic review and meta-analysis included 1131 participants from 19 unique RCTs.
Data extraction and quality assessment. Data were extracted according to a pre-established protocol. The following information was extracted from the included RCTs: general information (first authorÕs name, year of publication, title); study characteristics (study design, eligibility criteria, trial quality, intervention duration, and the form and amount of cocoa flavanol intake); participant characteristics (age, proportion of men, race/ethnicity, and comorbidities); and outcome measures (definition of outcomes, statistical methods, pre-and postintervention means and SDs, sample size of each arm, and adverse events). Methodologic quality was assessed with the use of the Cochrane CollaborationÕs tool for assessing the risk of bias (23) and included random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. For each trial, the risk of bias was reported as low, unclear, or high. The criteria used for quality assessment have been described in detail elsewhere (23) .
Data synthesis and analysis. Mean changes and SDs of cardiometabolic biomarkers from baseline in the treatment and placebo groups were used to calculate the weighted mean differences (WMDs) and 95% CIs with the use of the DerSimonian and Laird random-effects models (24) . Between-study heterogeneity was examined with the use of I 2 statistics (25), with an I 2 of 25%, 50%, and 75% denoting low, medium, and high heterogeneity, respectively. BeggÕs and EggerÕs tests formally tested for publication bias (26, 27) . If there were any evidence of publication bias, the trim and fill method evaluated its impact (28) .
Meta-regressions evaluated the overall impact of the predetermined potential modifiers, including study design, the form of cocoa flavanol intake, the amount of cocoa flavanol intake, age, sex, intervention duration, and existing comorbidity. Cutoffs of 200 and 600 mg/d for the categorical cocoa flavanol amount tested were selected based on prior knowledge and what has been used in previous studies. The categorical FIGURE 1 Flowchart of the study selection of 19 RCTs eligible for the meta-analysis. In total, 326 articles were identified that evaluated the effect of cocoa flavanols on cardiometabolic biomarkers. We excluded 239 articles after abstract review and 68 after full-text examination. After exclusion, 19 RCTs (n = 1131) were included in the meta-analysis. RCT, randomized control trial. 1 Supported by the NIH, American Heart Association, Mars Symbioscience, National Heart, Lung, and Blood Institute, and Pfizer. 2 Author disclosures: X Lin, I Zhang, A Li, and S Liu, no conflicts of interest. JE Manson, HD Sesso, and L Wang received support from Mars Symbioscience for investigator-initiated clinical trial testing cocoa flavanols. 3 The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. 4 Supplemental Figures 1-4 Cocoa flavanols and cardiometabolic health 3 of 9
at BROWN UNIVERSITY on October 16, 2016 jn.nutrition.org Downloaded from variable for intervention duration was created based on the median duration of all included RCTs. P # 0.05 was considered significant except for the tests of publication bias (P = 0.10) (29) . All statistical analyses were performed with Stata version 13 (StataCorp LP). Figure 1 shows how the participants from the 19 RCTs were selected for the meta-analysis. The actual number of studies synthesized varied across biomarkers. Characteristics of eligible trials are summarized in Table 1 . Among all participants, the proportion of men ranged from 0% to 100%, with a mean age of 30-71 y. The amount of cocoa flavanols tested for the RCTs ranged from 166 to 2110 mg/d, and intervention duration ranged from 2 to 52 wk. Among the included RCTs, 11 trials used a crossover design, 8 trials used a placebo-controlled parallel design, and 13 trials were conducted among participants with existing comorbidities, including hypertension, coronary artery disease, diabetes, overweight, hypercholesterolemia, metabolic syndrome, or mild cognitive impairment.
Results
Description of study quality. The quality of studies included was heterogeneous (Figure 2) . Random sequence generation and allocation concealment were reported in 6 trials. Allocation concealment was also reported in 6 trials. The risk of potential performance bias was low in 7 trials. Among 6 trials with available information on whether outcome assessment was blinded, the risk of detection bias was high in only 1 trial. The outcome data were incomplete in 2 trials. The risk of another bias was high in 2 trials because of poor compliance or other study-specific limitations. Lipid and lipoprotein biomarkers. The number of trials included for each lipid and lipoprotein biomarker is shown in Table 2 . Cocoa flavanol intake significantly lowered TGs (P < 0.001) and increased HDL cholesterol concentrations (P < 0.001) compared with placebo ( Table 2 Supplemental Figure 2) . The P values of the EggerÕs or BeggÕs tests for all lipid biomarkers were >0.10, suggesting that the small study effects were not significant. After correcting for multiple comparisons, the associations observed for TGs and HDL cholesterol remained significant (q = 0.002 and 0.003).
Biomarkers of insulin resistance. Table 2 also shows the effects of cocoa flavanol intake on insulin resistance. Fasting insulin concentrations and HOMA-IR were each significantly lower in the cocoa flavanol groups than the placebo group (each P < 0.001), whereas the quantitative insulin sensitivity check index (QUICKI) and insulin sensitivity index (ISI) were significantly improved among the cocoa flavanol groups compared with placebo (each P = 0.01) ( Supplemental Figure 4) . The WMD for QUICKI was 0.03 (95% CI: 0.01, 0.05; I 2 = 97%), and the WMD for ISI based on postintervention values was 2.54 (95% CI: 0.63, 4.44; I 2 = 86%) ( Table 2 ). There was no evidence of publication bias from the EggerÕs or BeggÕs tests (all P > 0.10). After correcting for multiple comparisons, the associations observed for insulin (q < 0.001), HOMA-IR (q < 0.001), QUICKI (q = 0.02), and ISI (q = 0.02) remained significant. Table 2 ). After correcting for multiple comparisons, the associations observed for C-reactive protein (q < 0.001) and VCAM-1 (q = 0.02) remained significant. With a relatively limited number of RCTs available, our analyses did not show any statistically significant overall effects of cocoa flavanols on biomarkers of oxidative stress.
Modifying effects of age, sex, duration, design, comorbidities, and form and amount of cocoa flavanols. Meta-regressions and subgroup analyses were conducted for biomarkers with $10 trials included in the primary analyses. Age and sex did not modify the effects of cocoa flavanol intake on lipid metabolism and insulin resistance (all P meta-regression $ 0.05). Cocoa flavanols improved the profiles of lipid metabolism and insulin resistance regardless of intervention duration, design, or Table 6 ).
Discussion
In this systematic review and meta-analysis of 1131 participants from 19 RCTs, we found that cocoa flavanol intake from cocoa products, chocolate, or cocoa flavanol supplements significantly improved biomarkers of lipid metabolism and insulin resistance. Our meta-analysis of RCTs is among the first to our knowledge to characterize how cocoa flavanols affect cardiometabolic biomarkers. We found that cocoa flavanol intake may reduce dyslipidemia, insulin resistance, and systemic inflammation, which are all major subclinical risk factors for cardiometabolic diseases.
The favorable associations between cocoa flavanols and cardiometabolic health have been reported in 3 major US prospective cohort studies: NursesÕ Health Study I, NursesÕ Health Study II, and the Health Professionals Follow-Up Study.
Wedick et al. (48) followed >130,000 women and men, identified 12,611 incident type 2 diabetes cases, and reported a modestly reduced risk in type 2 diabetes of similar magnitude across quintiles 2-5 of flavanol intake compared with the lowest quintile (pooled HRs: 0.92, 0.91, 0.94, and 0.91, respectively). Similar findings were also reported in the European Prospective Investigation into Cancer and Nutrition study (49, 50) . However, these findings were not confirmed in a study of 35,816 postmenopausal women (51) .
Flavanols have been shown to inhibit glucosidase and glucose absorption from the intestine, protect pancreatic b cells, increase insulin secretion, activate insulin receptors and glucose uptake in insulin-sensitive tissues, and modulate intracellular signaling pathways and genes involved in gluconeogenesis and glycogenesis (15, 52) . Flavanols may also improve insulin sensitivity by increasing NO bioavailability and inhibiting production of reactive oxygen species and nitrogen species (5, 6). The increased bioavailability of NO may also mediate the beneficial effects of cocoa flavanols on endothelial function (53) . Experimental studies have shown that cocoa supplementation slowed body weight gain, increased plasma concentrations of adiponectin, and attenuated insulin resistance, as indicated by improved HOMA-IR (54, 55) . In addition, a growing body of evidence derived from both in vitro studies and animal studies also demonstrates the antidyslipidemia and anti-inflammation effects of cocoa and cocoa flavanols (14, 56, 57) (58-60). However, evidence from humans is restricted to observational studies and smaller short-term trials. Only a few studies to our knowledge have synthesized the evidence for the effects of cocoa flavanol intake on specific biological parameters beyond those characterized by excess oxidative stress.
Previous reviews and meta-analyses have supported the notion that chocolate, cocoa products, and cocoa flavanol 
Biomarker
Crossover Parallel (10) showed that both flow-mediated dilation and HOMA-IR were also improved after chocolate consumption, and Shrime et al. (64) showed beneficial effects of cocoa products of lowering blood pressure and improving insulin sensitivity, lipid profiles, and flow-mediated dilation in a metaanalysis of short-term studies. Our updated meta-analysis of RCTs has not only updated previous findings (10) but also added cardiometabolic biomarkers involved in lipid metabolism, insulin resistance, systemic inflammation, renal function, and oxidative stress. Strengths of this meta-analysis include the synthesis of evidence from RCTs that examined both conventional and novel cardiometabolic biomarkers, detailed subgroup analyses for potential effect modifiers, and a comprehensive evaluation of potential bias. Our meta-analysis is among the first to our knowledge to synthesize evidence for the novel, less-studied cardiometabolic biomarkers. In addition, our subgroup analysis found that cocoa flavanol interventions may have consistent effects on the biomarkers of lipid metabolism and insulin resistance regardless of age, sex, existing comorbidities, intervention duration, RCT design, and the form and amount of cocoa flavanols. Although the meta-regression analysis showed that the difference between people with and without comorbidities did not reach statistically significant cutoffs, possibly because of the limited number of trials available, the benefits for people with existing comorbidities seemed to be more substantial than those without comorbidities, which warrant further investigations.
There are several potential limitations to our study. First, although 19 trials were included in the meta-analysis, the number of studies for a specific biomarker varied. The number of available RCTs is especially limited for lipoprotein(a), oxidized LDL, VCAM-1, and leptin. In addition, the effect sizes were small to moderate for most biomarkers. Therefore, findings for those biomarkers need to be confirmed by further investigations and interpreted with caution. In addition, the precision of the estimates from individual RCTs was subject to small samples and variable intervention durations. In addition to providing comprehensive evidence for biomarkers of lipid metabolism and insulin resistance, our study highlights the urgent need for large long-term RCTs that improve our understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes. Second, the subgroup analyses were restricted to biomarkers with $10 studies, and cutoffs used for categorizing modifiers were selected on an ad hoc basis. Third, because of the heterogeneity of cocoa flavanol interventions and limited evidence reported from RCTs, we were not able to distinguish the effects of different active compounds of cocoa flavanol-rich foods. However, we sought to maximize those data available from RCTs and found that any favorable effects of cocoa flavanols on cardiometabolic risk factors did not seem to be modified by the form or amount of cocoa flavanols. In addition, because of the limited number of trials available, studies that used different sources of blood for biomarker measurements were synthesized together, which may have introduced additional heterogeneity. Fourth, as shown in Figure 2 , our results may be prone to the inherent weaknesses of individual RCTs. In summary, our meta-analysis of RCTs indicates that cocoa flavanol intake from cocoa products, chocolate, or cocoa flavanol supplements may have modest but significant benefits in lipid metabolism, insulin resistance, and systemic inflammation. Further investigations, particularly large long-term RCTs, are urgently needed to confirm or refute whether cocoa flavanols represent a promising bioactive in the prevention of cardiometabolic diseases.
